Guizhi Fuling Wan as a Novel Agent for Intravesical Treatment for Bladder Cancer in a Mouse Model

Molecular Medicine
Chi-Chen LuCheng-Da Hsu

Abstract

Alternative intravesical agents are required to overcome the side effects currently associated with the treatment of bladder cancer. This study used an orthotopic bladder cancer mouse model to evaluate Guizhi Fuling Wan (GFW) as an intravesical agent. The effects of GFW were compared with those of mitomycin-C (Mito-C) and bacille Calmette-Guérin (BCG). We began by evaluating the response of the mouse bladder cancer cell line MB49 to GFW treatment, with regard to cell viability, cell cycle progression and apoptosis. MB49 cells were subsequently implanted into the urothelial walls of the bladder in female C57BL/6 mice. The success of the model was confirmed by the appearance of hematuria and tumor growth in the bladder. Intravesical chemotherapy was administered in accordance with a published protocol. In vitro data revealed that GFW arrested MB49 cell cycle in the G0/G1 phase, resulting in the suppression of cell proliferation and induced apoptosis. One possible mechanism underlying these effects is an increase in intracellular reactive oxygen species (ROS) levels leading to the activation of ataxia telangiectasia-mutated (ATM)/checkpoint kinase 2 (CHK2) and ATM/P53 pathways, thereby mediating cell cycle progression and apoptosi...Continue Reading

References

Dec 16, 1994·Science·L H Hartwell, M B Kastan
Jan 1, 1996·International Urology and Nephrology·V UlkerG Kandiloğlu
Feb 15, 2000·Annals of the New York Academy of Sciences·I Fridovich
Apr 30, 2002·Free Radical Biology & Medicine·Rodney L Levine
Aug 27, 2002·Journal of Clinical Pathology·A Lopez-BeltranR Montironi
Oct 4, 2002·Nutrition·Yun-Zhong FangGuoyao Wu
Jun 20, 2003·Cell Proliferation·Katrien VermeulenDirk R Van Bockstaele
Nov 13, 2003·Molecular and Cellular Biology·Salvador MacipStuart A Aaronson
Jan 15, 2004·The Journal of Clinical Investigation·Pascal KahlemClemens A Schmitt
Nov 13, 2007·The Journal of Urology·M Craig HallPaul F Schellhammer
Apr 9, 2008·Current Opinion in Oncology·Daniel A Barocas, Peter E Clark
Sep 2, 2008·Journal of Ethnopharmacology·Zhang Yao, Zhang Shulan
Nov 4, 2008·Carcinogenesis·Scott MaynardVilhelm A Bohr
Nov 13, 2008·Apoptosis : an International Journal on Programmed Cell Death·Ruifen ZhangSanjay K Srivastava
May 29, 2009·Mutation Research·Soumya ChatterjeeArindam Bhattacharyya
Jun 23, 2010·CA: a Cancer Journal for Clinicians·Bruce L JacobsJames E Montie
Oct 23, 2010·Science·Zhi GuoTanya T Paull
Nov 3, 2010·Advances in Cancer Research·Joanne SmithDavid A Gillespie
Oct 1, 2011·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Qingyong LiLi Zhang
Feb 13, 2014·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey S DamrauerWilliam Y Kim

❮ Previous
Next ❯

Citations

Jan 25, 2018·Journal of Cellular Biochemistry·Barbara Prack Mc CormickAna M Eiján
Oct 27, 2017·International Journal of Molecular Sciences·Yasuyoshi MiyataHideki Sakai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.